Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants.

Ashley C BeavisZhuo LiKelsey BriggsMaría Cristina Huertas-DíazElizabeth R WrobelMaria NajeraDong AnNichole Orr-BurksJackelyn MurrayPreetish PatilJiachen HuangJarrod MousaLinhui HaoTien-Ying HsiangMichael GaleStephen B HarveyS Mark TompkinsRobert Jeffrey HoganEric R LafontaineHong JinBiao He

Published in: bioRxiv : the preprint server for biology (2022)

With emerging new variants of concern (VOC), SARS-CoV 2 continues to be a major threat to human health. Approved COVID-19 vaccines have been less effective against these emerging VOCs. This work demonstrates the protective efficacy, and strong boosting effect, of a new intranasal viral-vectored vaccine against SARS-CoV-2 variants in hamsters.

Keyphrases

sars cov
human health
copy number
respiratory syndrome coronavirus
risk assessment
climate change
coronavirus disease
gene expression
respiratory syncytial virus